GT
GT Biopharma, Inc.
GTBP · NASDAQ
$7.49 -1.38% (-$0.10)
1M +8.93%
Market Cap $9.45M
P/E Ratio -
Div. Yield -
ROE 443.08%
Bulios Fair Price
$5.4
27.9% downside
Trenutna cena
$7.49
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica GTBP trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
1/9Valuation
73 /100
Cheap P/B 2.65x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 20.99%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 457.75%
Asset turnover 0.00x
ROE 443.08%
Debt
69 /100
Low Debt/Equity 0.00x
Int. coverage -160.04x
Current ratio 2.61x
Stability
36 /100
Moderate Beta 0.91x
Profitable years 0
EPS volatility 432.17%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o GTBP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Martin Breen
Employees
1
Headquarters
San Francisco
Prihajajoči dogodki
13 NOV.
Earnings
Upcoming earnings report